The historically mixed data and the need to control for confounding required further investigation into the association between use of progestogen‑only injectables and increased risk of HIV acquisition, using a more robust research design. This led to the development of the Evidence for Contraceptive Options and HIV Outcomes (ECHO) trial.
The results of the ECHO trial were published in the Lancet on 13 June 2019. The ECHO trial finds no link between HIV acquisition and the use of DMPA-IM, progestogen implant, and non-hormonal copper IUD.
At A Glance provides a pocket sized summary of the Annual Performance data for easy on demand data to answer all your questions. At A Glance is available also in Arabic, French, Portuguese and Spanish.
This Annual Performance Report presents progress in implementing the Strategic Framework. In 2018, IPPF delivered 223.2 million sexual and reproductive health services and contributed to 163 policy and legal changes in support of sexual and reproductive health and rights. Each ...
Cervical cancer, a preventable illness, is the fourth most frequent cancer in women, with an estimated 570,000 new cases in 2018 representing 6.6% of all female cancer. An increasing number of SRH organizations are working to introduce and/or strengthen cervical cancer prevention programmes with the aim of increasing their impact on the reduction of mortality and morbidity. IPPF´s work on cervical cancer prevention is guided by our commitment to health equity, gender equality and women’s rights.
To improve the quality and availability of post‑abortion care during a flood, the Innovation Programme supported the University of Leicester to develop and measure the impact of an integrated intervention package, called RHCC.